Based on the current week's news, the sentiment is NEUTRAL to POSITIVE for Dr. Reddy's stock.

Notable events:

* Dr. Reddy's share price closed at ₹1240.65, up 0.37% from yesterday's ₹1236.10, indicating a slight increase.
* The company entered into a collaboration with Henlius for the commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S. and Europe.
* Dr. Reddy's also signed a pact with Shanghai Henlius Biotech for exclusive US and Europe rights for daratumumab biosimilar.

Historical analysis suggests that similar news events have had mixed impacts on the stock price in the past. However, the current news tone is more positive, with the collaboration and pact announcements indicating potential growth opportunities for the company.

Overall, the news tone is NEUTRAL to POSITIVE, suggesting that the stock may experience a slight increase or remain stable in the short term.